Quality‐of‐life scores improve after 96 weeks of PEG‐IFNa‐2a treatment of hepatitis D: An analysis of the HIDIT‐II trial

Infection with the hepatitis D virus (HDV) causes the most severe form of viral hepatitis with a high risk to develop clinical complications of liver disease. In addition, hepatitis delta has been shown to be associated with worse patient‐reported outcomes. Until recently, only pegylated interferon alfa could be used to treat hepatitis delta.

[1]  H. Wedemeyer,et al.  Interferon‐based treatment of chronic hepatitis D , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[2]  M. Buti,et al.  Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks , 2022, Journal of Hepatology.

[3]  P. Lampertico,et al.  BULEVIRTIDE WITH OR WITHOUT PEGIFNα FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES. , 2022, Journal of hepatology.

[4]  Ming‐Lung Yu,et al.  Itemization difference of patient-reported outcome in patients with chronic liver disease , 2022, PloS one.

[5]  P. Lampertico,et al.  Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease , 2021, Gut.

[6]  H. Wedemeyer,et al.  Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatitis C‐Registry (DHC‐R) , 2021, Journal of viral hepatitis.

[7]  M. Buti,et al.  Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B , 2021, JHEP reports : innovation in hepatology.

[8]  F. Roudot-thoraval,et al.  Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis Delta. , 2020, Journal of hepatology.

[9]  C. de Martel,et al.  The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis , 2020, Journal of hepatology.

[10]  O. Weiland,et al.  Long‐Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver‐Related Outcomes , 2020, Hepatology.

[11]  F. Negro,et al.  Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. , 2020, Journal of hepatology.

[12]  M. Manns,et al.  Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. , 2019, The Lancet. Infectious diseases.

[13]  R. Idilman,et al.  Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease , 2018, The Journal of infectious diseases.

[14]  M. Manns,et al.  Antiviral treatment and liver‐related complications in hepatitis delta , 2017, Hepatology.

[15]  H. Günthard,et al.  Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. , 2017, Journal of hepatology.

[16]  M. Manns,et al.  Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity , 2015, European journal of gastroenterology & hepatology.

[17]  V. Soriano,et al.  Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Manns,et al.  Development and evaluation of a baseline-event-anticipation score for hepatitis delta , 2014, Journal of viral hepatitis.

[19]  V. Strand,et al.  Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study , 2013, Health and Quality of Life Outcomes.

[20]  H. Tillmann,et al.  Quality of life in patients with various liver diseases , 2011, Journal of viral hepatitis.

[21]  M. Manns,et al.  Peginterferon plus adefovir versus either drug alone for hepatitis delta. , 2011, The New England journal of medicine.

[22]  R. Navinés,et al.  Pegylated interferon and ribavirin-induced depression in chronic hepatitis C: role of personality. , 2009, The Journal of clinical psychiatry.

[23]  M. Kosinski,et al.  Evaluation of the meaningfulness of health‐related quality of life improvements as assessed by the SF‐36 and the EQ‐5D VAS in patients with active Crohn’s disease , 2009, Alimentary pharmacology & therapeutics.

[24]  J. Borovička,et al.  Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection , 2008, Gut.

[25]  C. Trépo,et al.  Interferon-based treatment of chronic hepatitis C. , 2007, Biochimie.

[26]  R. Fontana,et al.  Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. , 2007, Journal of hepatology.

[27]  M. Scheurlen,et al.  Neurocognitive Changes in Patients with Hepatitis C Receiving Interferon alfa‐2b and Ribavirin , 2005, Clinical pharmacology and therapeutics.

[28]  T. Wise,et al.  Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. , 2004, Cleveland Clinic journal of medicine.

[29]  M. Scheurlen,et al.  Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. , 2003, The Journal of clinical psychiatry.

[30]  G. Guyatt,et al.  Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease , 1999, Gut.

[31]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[32]  John E. Ware,et al.  The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection , 1992, Medical care.

[33]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[34]  Monika Bullinger,et al.  SF-36, Fragebogen zum Gesundheitszustand , 1998 .